Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2016
43p drug that prevents spread of breast cancer denied to thousands
22 September 2016 - Thousands of women in the UK with breast cancer are being denied a 43p-a-day medicine ...
Posted by Michael Wonder on 22 Sep 2016
NICE to recommend new drug to treat rare inherited bone disorder in children
22 September 2016 - NICE recommends ‘lifeline’ drug for babies and young children, in draft guidance. ...
Posted by Michael Wonder on 22 Sep 2016
The pill: Lower-income women locked out of new contraceptive ranges
23 September 2016 - Yasmin, Juliette, Diane, Brenda. The names are instantly recognisable to many women who take the contraceptive pill. ...
Posted by Michael Wonder on 22 Sep 2016
CADTH calls for patient input on a resubmission from NovoNordisk for Victoza (liraglutide)
21 September 2016 - CADTH is calling for patient input on a resubmission from Novo Nordisk for Victoza (liraglutide). ...
Posted by Michael Wonder on 21 Sep 2016
Dual-attack lobbyists target Sussan Ley over PBS and prostheses
22 September 2016 - Lobbyists pushing for medical device manufacturers to maintain their lucrative deals on the government’s prostheses list also ...
Posted by Michael Wonder on 20 Sep 2016
Generic Medicines Working Group communique
20 September 2016 - The communique from the July 2016 meeting of the Generic Medicines Working Group is now available, ...
Posted by Michael Wonder on 20 Sep 2016
Biosimilar awareness initiative reference group communique
20 September 2016 - The communique from the third Reference Group meeting is now available. ...
Posted by Michael Wonder on 19 Sep 2016
Agenda for 21 September 2016 TC meeting
19 September 2016 - The Transparency Commission will consider the reimbursement of a number of new medicines and blood products. ...
Posted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
Posted by Michael Wonder on 19 Sep 2016
NICE says no to expanding scope of Roche’s IPF drug
19 September 2016 - Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait ...
Posted by Michael Wonder on 19 Sep 2016
Real-world evidence: a comparison of the Australian Herceptin Program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer
19 September 2016 - Estimating the real-world cost-effectiveness of a new drug relies on understanding the differences between clinical trial data ...
Posted by Michael Wonder on 17 Sep 2016
Selexipag in pulmonary arterial hypertension: additional clinical benefit is not proven
16 September 2016 - Limited comparator therapy and division of population inadequate/the only study compared the medicine with placebo. ...
Posted by Michael Wonder on 16 Sep 2016
CADTH drug portfolio information sessions
16 September 2016 - The CADTH Drug Portfolio Information Sessions are an opportunity for stakeholders to receive an update on the ...
Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects. ...
Posted by Michael Wonder on 15 Sep 2016
NICE published draft guidance on new use for Gazyva
15 September 2016 - The Department of Health has asked the NICE to produce guidance on using obinutuzumab in combination with ...